ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly trajenta (linagliptin) — Outside U.S. revenue ($M) [legacy] ($M)
Quarterly figures from Eli Lilly's filings and investor materials
Latest, Q4 2020
65.8
Period ended Dec 31, 2020
Change on a year earlier
-31.7%
96.3 in Q4 2019
History
16 quarters
Since Q1 2017
Sources
12
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Trajenta (linagliptin) — Outside U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2020 | Dec 31, 2020 | 65.8 | -31.7% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2020 | Sep 30, 2020 | 72.3 | -24.2% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2020 | Jun 30, 2020 | 60.5 | -32.4% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 64.5 | -23.8% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 96.3 | +3.2% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 95.4 | +11.8% | Form 10-Q (filed 2020-10-28) ↗ |
| Q2 2019 | Jun 30, 2019 | 89.5 | +5.4% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2019 | Mar 31, 2019 | 84.6 | -2.8% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 93.3 | +3.0% | Form 10-K (filed 2021-02-17) ↗ |
| Q3 2018 | Sep 30, 2018 | 85.3 | +0.5% | Form 10-Q (filed 2019-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 84.9 | +4.2% | Form 10-Q (filed 2019-08-02) ↗ |
| Q1 2018 | Mar 31, 2018 | 87 | +28.7% | Form 10-Q (filed 2019-05-02) ↗ |
| Q4 2017 | Dec 31, 2017 | 90.6 | – | Form 10-K (filed 2020-02-19) ↗ |
| Q3 2017 | Sep 30, 2017 | 84.9 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 81.5 | – | Form 10-Q (filed 2018-07-25) ↗ |
| Q1 2017 | Mar 31, 2017 | 67.6 | – | Form 10-Q (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Eli Lilly Trajenta (linagliptin) — Outside U.S. revenue ($M) [legacy] ($M), quarterly Q1 2017–Q4 2020 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_trajenta_nonus
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.